Fougera's generic Differin gets green light from FDA

MELVILLE, N.Y. The Food and Drug Administration has approved a topical drug for acne made by E. Fougera, the generic drug maker said Tuesday.

The FDA approved Fougera’s adapalene cream in the 0.1% strength, a generic version of Galderma Pharmaceuticals’ Differin. Fougera is the first company to win approval for a generic version of the drug.

“Fougera’s commitment to develop this first-to-market product as a cost-effective generic provides healthcare professionals the ability to prescribe a more affordable treatment, thereby making it accessible to more patients,” Fougera SVP and general manager David Klaum said.

Differin had sales of more than $55 million in 2009, according to industry sources cited by Fougera.

Login or Register to post a comment.